The Added Value of Concurrently-Administered Temozolomide Versus Adjuvant Temozolomide Alone in Newly-Diagnosed Glioblastoma

PURPOSE: Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM). However, it is unclear whether its primary mechanism of action is through enhancement of radiation response or through indepen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sher, David J., Henson, John, Avutu, Bindu, Hochberg, Fred, Batchelor, Tracy, Martuza, Robert, Barker, Fred, Loeffler, Jay S., Chakravarti, Arnab
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2658810/
https://ncbi.nlm.nih.gov/pubmed/18231723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-008-9530-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars